The Cardioprotective Effects of Semaglutide in Obese Patients: Literature Review
DOI:
https://doi.org/10.37497/JMRReview.v3i00.59Keywords:
Cardioprotective effects, Semaglutide, Obesity, ReviewAbstract
Introduction: Obesity is an independent risk factor for cardiovascular disease (CVD) as it increases inflammation and oxidative stress in the body. Glucagon Like Peptide-1 (GLP-1 RA) agonist receptors, such as semaglutide, reduce weight, improve blood sugar levels, and promote cardioprotection. GLP-1 Ras extend the life of GLP-1, an incretin responsible for processes that decrease hyperglycemia, leading to weight loss.
Objective: To understand the cardioprotective effects of semaglutide in obese patients.
Method: We conducted a literature review focusing on identifying the cardioprotective effects of semaglutide use in obese patients.
Results and Discussion: The hyperglycemic and pro-inflammatory state of obese individuals favors pro-thrombotic mechanisms and cardiovascular dysfunction. GLP-1 Ras mediate their effects through the GLP-1 receptor, showing a reduced risk of CVD as they have beneficial effects on reducing blood pressure, weight, lipid levels, and glucose. Semaglutide acts as a long-acting GLP-1 RA, demonstrating a greater ability to reduce weight within this class, and works by stimulating insulin secretion by pancreatic beta cells and reduces glucagon production by alpha pancreatic cells.
Conclusion: According to the literature, it is possible to consider that semaglutide promotes cardioprotection in obese patients. However, further studies are still needed to confirm this relationship and achieve greater efficacy in treatment.
References
ARD, J. et al. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Advances in Therapy, v. 38, n. 6, p. 2821–2839, May 11, 2021.
ATEF, M. M. et al. The cardioprotective effect of human glucagon-like peptide-1 receptor agonist (semaglutide) on cisplatin-induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways. Cell Biochemistry and Function, v. 41, n. 4, p. 450–460, Jun 1, 2023.
BAGGIO, L. L.; DRUCKER, D. J. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Molecular Metabolism, v. 46, p. 101090, Apr 2021.
CHAO, A. M. et al. Semaglutide for the treatment of obesity. Trends in Cardiovascular Medicine, v. 33, n. 3, Dec 2021.
CHRISTOU, G. A. et al. Semaglutide as a promising antiobesity drug. Obesity Reviews, v. 20, n. 6, p. 805–815, Feb 15, 2019.
GOLDENBERG, R. M.; STEEN, O. Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. Canadian Journal of Diabetes, v. 43, n. 2, p. 136–145, Mar 2019.
KOSIBOROD, M. N. et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes, Obesity and Metabolism, Oct 28, 2022.
LINGVAY, I. et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity, v. 31, n. 1, p. 111–122, Dec 10, 2022.
MICHAEL LINCOFF et al, Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, The New England Journal of Medicine, v. 389, 2023.
PAN, X. et al. Single-cell transcriptome reveals effects of semaglutide on non-cardiomyocytes of obese mice. Biochemical and Biophysical Research Communications, v. 622, p. 22–29, Sep 24, 2022.
PAN, Xiaoyu; YANG, Lin; WANG, Shuqi; et al. Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression. Molecular and Cellular Biochemistry, 2023.
PEDROSA, M. R. et al. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? Current Atherosclerosis Reports, Aug 31, 2022.
PREDA, A. et al. Obesity phenotypes and cardiovascular risk: From pathophysiology to clinical management. Jun 26, 2023.
RYAN, Donna H.; LINGVAY, Ildiko; COLHOUN, Helen M.; et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. American Heart Journal, v. 229, p. 61–69, 2020.
SINGH, G.; KRAUTHAMER, M.; BJALME-EVANS, M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine, v. 70, n. 1, p. jim-2021-001952, Oct 27, 2021.
SIRAJ, M. A. et al. Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α. Journal of Clinical Investigation, v. 130, n. 3, p. 1392–1404, Jan 27, 2020.
TIRANDI, A. et al. Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists. Polish Archives of Internal Medicine, p. 16658, Jan 9, 2024. Available at: <https://pubmed.ncbi.nlm.nih.gov/38226456/>. Accessed on: Feb 7, 2024.
TIRANDI, Amedeo; MONTECUCCO, Fabrizio; CARBONE, Federico; et al. Obesity, cardiovascular, and cerebrovascular disease: the role of GLP-1 receptor agonists. Polish Archives of Internal Medicine, p. 16658,2024. Available at: <https://pubmed.ncbi.nlm.nih.gov/38226456/>. Accessed on: February 7, 2024.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
O(s) autor(es) autoriza(m) a publicação do texto na da revista;
O(s) autor(es) garantem que a contribuição é original e inédita e que não está em processo de avaliação em outra(s) revista(s);
A revista não se responsabiliza pelas opiniões, idéias e conceitos emitidos nos textos, por serem de inteira responsabilidade de seu(s) autor(es);
É reservado aos editores o direito de proceder a ajustes textuais e de adequação às normas da publicação.
Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado (Veja O Efeito do Acesso Livre) em http://opcit.eprints.org/oacitation-biblio.html
